Thomas Jensen

Background

About Thomas Jensen

I have dedicated my career to bridging advanced science, effective laboratory techniques, and bioinformatics—most notably through my contributions to building Allarity Therapeutics, a company rooted in innovative mRNA expression profiling and a deep commitment to developing personalized cancer therapies. At the core of our approach is the DRP® (Drug Response Predictor) platform, a proprietary companion diagnostic technology. Today, I serve as CEO of Allarity Therapeutics, and under my leadership, the company has become increasingly focused on advancing stenoparib—a differentiated, dual-targeted PARP/Wnt pathway inhibitor—through Phase 2 development for hard-to-treat cancers, including advanced ovarian cancer. Stenoparib has demonstrated durable clinical benefit in heavily pre-treated patients and is distinguished by a favorable safety profile and a novel mechanism of action. I remain committed to executing our strategy, securing the capital needed to drive our programs forward, and positioning Allarity for long-term success as we strive to bring better treatment options to cancer patients around the world.